The
lack of safe and effective delivery across the blood-brain
barrier and the profound immune suppressive microenvironment are two
main hurdles to glioblastoma (GBM) therapies. Extracellular vesicles
(EVs) have been used as therapeutic delivery vehicles to GBM but with
limited efficacy. We hypothesized that EV delivery to GBM can be enhanced
by (i) modifying the EV surface with a brain-tumor-targeting cyclic
RGDyK peptide (RGD-EV) and (ii) using bursts of radiation for enhanced
accumulation. In addition, EVs were loaded with small interfering
RNA (siRNA) against programmed cell death ligand-1 (PD-L1) for immune
checkpoint blockade. We show that this EV-based strategy dramatically
enhanced the targeting efficiency of RGD-EV to murine GBM, while the
loaded siRNA reversed radiation-stimulated PD-L1 expression on tumor
cells and recruited tumor-associated myeloid cells, offering a synergistic
effect. The combined therapy significantly increased CD8+ cytotoxic T cells activity, halting tumor growth and prolonging
animal survival. The selected cell source for EVs isolation and the
presented functionalization strategy are suitable for large-scale
production. These results provide an EV-based therapeutic strategy
for GBM immune checkpoint therapy which can be translated to clinical
applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.